Mechanism difference Semaglutide (GLP-1 agonist): appetite regulation, satiety, improved glycemic control (New England Journal of Medicine) Tirzepatide (GLP-1/GIP agonist): broader incretin effects, robust appetite/weight effects (New England Journal of Medicine) AOD-9604: targeted fat-metabolism signaling
5-Amino-1MQ inhibits an enzyme (NNMT) rather than activating a receptor, so its effect persists 1824 hours regardless of meal timing or activitymaking it less time-sensitive
What are BPC-157 & TB-500 Peptides
Sermorelin, also a GHRH analog, was once FDA-approved for pediatric GH deficiency but is no longer marketed
- 5-Amino-1MQ is studied in research models involving NNMT pathway activity, NAD+-adjacent metabolism, adipocyte biology, methylation-related signaling, cellular energy regulation, and body-composition pathway research